# A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita

> **NCT05180708** · PHASE3 · COMPLETED · sponsor: **Palvella Therapeutics, Inc.** · enrollment: 87 (actual)

## Conditions studied

- Pachyonychia Congenita

## Interventions

- **DRUG:** QTORIN 3.9% rapamycin anhydrous gel
- **DRUG:** Vehicle

## Key facts

- **NCT ID:** NCT05180708
- **Lead sponsor:** Palvella Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-29
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2024-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05180708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05180708, "A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05180708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*